The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Contemporary real-world evidence in unresectable HCC (uHCC) patients treated with regorafenib in Taiwan: Interim results from the observational REFINE study.
 
Shi-Ming Lin
No Relationships to Disclose
 
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Ono Pharmaceutical; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD; Ono Pharmaceutical; Roche/Genentech
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); MSD (Inst); Nucana (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Ono Pharmaceutical; Roche/Genentech
 
Long-Bin Jeng
No Relationships to Disclose
 
Yih-Jyh Lin
No Relationships to Disclose
 
Ming-Yang Lee
No Relationships to Disclose
 
Teng-Yu Lee
Consulting or Advisory Role - Bayer; Eisai; Gilead Sciences
Research Funding - MSD
 
Yi-Hsiang Huang
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; Ipsen; Lilly; MSD; Ono Pharmaceutical; Roche
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; Ipsen; Lilly; MSD; Ono Pharmaceutical; Roche
Research Funding - Bristol-Myers Squibb; Gilead Sciences